Cabozantinib Development Program

Discovered by Exelixis, and the focus of our development and commercialization efforts, Cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET and is recognized for its potential to treat a wide variety of cancers.

Download the PDF.

R & D
Pipeline Overview
Early-Stage Compounds
Cabozantinib Pipeline
Other Partnered Programs
Clinical Trials

Filter by Therapeutic Area

- Adrenal Tumors
- Adrenocortical Carcinoma
- Any GU Tumors
- Bladder Cancer
- Breast Cancer
- Colorectal Cancer (CRC)
- Differentiated Thyroid Cancer (DTC)
- Endometrial Cancer
- Esophageal Cancer
- Gastroesophageal Cancer
- Gastrointestinal (GI) Cancers
- Gastrointestinal Stromal Tumor (GIST)
- Genitourinary (GU) Cancers
- Germ Cell Tumors
- Gynecologic Cancers
- Head and Neck Cancer
- Hepatocellular Carcinoma (HCC)
- Lung Cancer
- Melanoma
- Mesothelioma
- Multiple Solid Tumor Types
- Neuroendocrine Tumors (NET) & Carcinoid
- Neurofibroma
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Pediatric Cancer
- Pediatric Glioma
- Pediatric Multiple Tumor Types
- Pediatric Neurofibroma
- Pediatric Sarcoma
- Prostate Cancer
- Rare GU Tumors
- Renal Cell Carcinoma (RCC)
- Sarcoma
- Squamous Cell Carcinoma
- Thyroid Cancer
- Urothelial Carcinoma (UC)

Clear Filters

Exelixis-Sponsored Trial | Roche-Sponsored Trial | Bristol Myers Squibb-Sponsored Trial | Investigator-Sponsored Trial | Collaboration with NCI's Cancer Therapy Evaluation Program | Sponsored by the European Organisation for Research and Treatment of Cancer (EORTC)

PHASE 1 | PHASE 2 | PHASE 3

Collapse All

Genitourinary (GU) Cancers

Phase 1

Cabozantinib + Nivolumab +/- CBM588
(Metastatic RCC)
Renal Cell Cancer

CABIOS: Cabozantinib + Abiraterone + Nivolumab
(Metastatic Hormone-Sensitive Prostate Cancer)
Prostate Cancer

Cabozantinib + Enfortumab Vedotin
(Locally Advanced or Metastatic UC)
Urothelial Carcinoma

COSMIC-021: Cabozantinib
(Advanced UC)
Urothelial Carcinoma

COSMIC-021: Cabozantinib + Atezolizumab
(Advanced RCC, Advanced UC & CRPC)
Renal Cell Carcinoma / Urothelial Carcinoma / Prostate Cancer

Cabozantinib + Nivolumab ± Ipilimumab
Any GU Tumors

Cabozantinib + avelumab
(Metastatic Renal Cell Carcinoma)
Renal Cell Carcinoma

Phase 2

Cabozantinib
(Refractory Germ Cell Tumors)
Germ Cell Tumors

Cabozantinib
(Metastatic CRPC with Genomic Alterations)
Prostate Cancer

Cabozantinib + Nivolumab + Ipilimumab
(Advanced Non-Clear Cell Renal Carcinoma)
Renal Cell Carcinoma

Cyto-KIK: CYTO Reductive Surgery followed by Cabozantinib + Nivolumab
(Metastatic RCC)
Renal Cell Carcinoma

ABATE: Cabozantinib + Atezolizumab
(Muscle-Invasive Bladder Cancer)
Bladder Cancer

PemCab: Cabozantinib + Pembrolizumab
(Metastatic UC Ineligible for Cisplatin)
Bladder Cancer / Urothelial Carcinoma

RadiCaL: Cabozantinib + Radium-223 Dichloride
(Advanced RCC with Bone Metastasis)
Renal Cell Carcinoma

Cabozantinib
(Advanced or metastatic urothelial carcinoma)
Renal Cell Carcinoma

Cabozantinib
(Clear Cell or Non-Clear Cell Metastatic RCC)
Renal Cell Carcinoma

ATLANTIS: Cabozantinib
(Metastatic Urothelial Carcinoma)
Renal Cell Carcinoma

Phase 3

CONTACT-03: Cabozantinib + Atezolizumab vs. Cabozantinib
(Advanced RCC)
Renal Cell Carcinoma

CONTACT-02: Cabozantinib + Atezolizumab vs. Second Novel Hormone Therapy
(Metastatic, Castrate-Resistant PC)
Prostate Cancer

COSMIC-313: Cabozantinib + Nivolumab + Ipilimumab
(First-line Advanced or Metastatic RCC)
Renal Cell Carcinoma

PDIGREE: Nivolumab + Ipilimumab followed by Cabozantinib + Nivolumab vs. Nivolumab
(First-line Metastatic RCC)
Renal Cell Carcinoma

Gastrointestinal (GI) Cancers

Phase 1

Cabozantinib + TAS-102
(Metastatic Colorectal Adenocarcinoma)
Colorectal Carcinoma

CAMILLA: Cabozantinib + Durvalumab
(Advanced CRC & HCC)
Colorectal Cancer / Hepatocellular Carcinoma

Cabozantinib ± Nivolumab
(Neoadjuvant, Locally Advanced HCC)
Hepatocellular Carcinoma

COSMIC-021: Cabozantinib + Atezolizumab
(HCC & CRC)
Colorectal Cancer / Hepatocellular Carcinoma

Phase 2

Cabozantinib + Pembrolizumab
(Metastatic Pancreatic Adenocarcinoma)
Pancreatic Cancer

Cabozantinib + Atezolizumab
(Metastatic, Refractory Pancreatic Cancer)
Pancreatic Cancer

Cabozantinib + Nivolumab
(Refractory Metastatic Microsatellite Stable CRC)
Colorectal Carcinoma

Cabozantinib + Pembrolizumab
(Advanced HCC)
Hepatocellular Carcinoma

Cabozantinib + Nivolumab/Ipilimumab and TACE
(Hepatocellular Carcinoma)
Hepatocellular Carcinoma

Cabozantinib
(Advanced Hepatocellular Carcinoma with Child-Pugh Class B Cirrhosis after First-Line Therapy)
Hepatocellular Carcinoma

CheckMate 040 Subgroup: Cabozantinib + Nivolumab ± Ipilimumab
(First-line and Previously Treated Advanced HCC)
Hepatocellular Carcinoma

Cabozantinib
(Refractory, Metastatic CRC)
Colorectal Cancer

Cabozantinib + pembrolizumab
(Metastatic or Recurrent Gastric or Gastro-Esophageal Adenocarcinoma)
Gastroesophageal Cancer

Phase 3

COSMIC-312: Cabozantinib + Atezolizumab vs. Sorafenib vs. Cabozantinib
(First-line Advanced HCC)
Hepatocellular Carcinoma

Thyroid Cancer

Phase 1

COSMIC-021: Cabozantinib + Atezolizumab
(DTC)
Differentiated Thyroid Cancer

Phase 2

Cabozantinib
(First-line, RAI-refractory DTC)
Differentiated Thyroid Cancer

Lung Cancer

Phase 1

COSMIC-021: Cabozantinib
(NSCLC)
Non-Small Cell Lung Cancer

COSMIC-021: Cabozantinib + Atezolizumab
(NSCLC)
Non-Small Cell Lung Cancer

Phase 2

Cabozantinib vs. Cabozantinib + Nivolumab vs. Chemotherapy
(Previously Treated Non-Squamous NSCLC)
Non-Small Cell Lung Cancer

Cabozantinib
(Molecular Alterations in RET, ROS1, MET, AXL, or NTRK1)
Non-Small Cell Lung Cancer

Nivolumab vs. Cabozantinib + Nivolumab vs. Cabozantinib + Nivolumab + Ipilimumab
(NSCLC)
Non-Small Cell Lung Cancer

Phase 3

CONTACT-01: Cabozantinib + Atezolizumab vs. Docetaxel
(Metastatic NSCLC)
Non-Small Cell Lung Cancer

Gynecologic Cancers

Phase 1

COSMIC-021: Cabozantinib + Atezolizumab
(EC, Ovarian Cancer & Breast Cancer)
Breast Cancer / Ovarian Cancer / Endometrial Cancer

Phase 2

Nivolumab ± Cabozantinib
(Advanced or Metastatic EC)
Endometrial Cancer

Neuroendocrine Tumors (NET) & Carcinoid

Phase 2

Cabozantinib
(Neuroendocrine Neoplasms)
NET & Carcinoid

Cabozantinib + Nivolumab + Ipilimumab
(Poorly Differentiated Neuroendocrine Carcinomas)
NET & Carcinoid

Cabozantinib + Nivolumab
(Advanced Carcinoid Tumors)
NET & Carcinoid

Cabozantinib
(Advanced Pancreatic NET & Advanced Carcinoid)
NET & Carcinoid

Phase 3

CABINET: Cabozantinib vs. Placebo
(Advanced Neuroendocrine Tumors After Progression on Everolimus)
NET & Carcinoid

Adrenocortical Carcinoma

Phase 2

Cabozantinib
(Metastatic Pheochromocytomas and Paragangliomas)
Adrenal Tumors

Cabozantinib
(Metastatic Adrenocortical Carcinoma)
Adrenal Tumors

Sarcoma

Phase 2

Cabozantinib + Nivolumab (Taxane Pre-treated) vs. Paclitaxel ± Nivolumab (Taxane Naive)
(Angiosarcoma)
Sarcoma

Cabozantinib + PD-1 and CTLA-4 Inhibition
(Metastatic Soft Tissue Sarcoma)
Sarcoma

Cabozantinib + Radiation Therapy
(Sarcomas of the Extremities)
Sarcoma

Cabozantinib + Temozolomide
(Unresectable or Metastatic Leiomyosarcoma and other Soft Tissue Sarcomas)
Sarcoma

Cabozantinib vs. Placebo
(High-Grade Uterine Sarcoma)
Sarcoma

Cabozantinib
(Metastatic Soft Tissue Sarcoma)
Sarcoma

Neurofibroma

Phase 2

Cabozantinib in Plexiform Neurofibromas
Neurofibroma

Gastroesophageal Cancer

Phase 1

CAMILLA: Cabozantinib + Durvalumab
(Advanced Gastric, Gastroesophageal or Esophageal Adenocarcinoma)
Gastroesophageal Cancer / Esophageal Cancer

COSMIC-021: Cabozantinib + Atezolizumab
(Gastric or Gastroesophageal Junction Adenocarcinoma)
Gastroesophageal Cancer

Head and Neck Cancer

Phase 1

Cabozantinib + Cetuximab
(Recurrent, Metastatic Squamous Cell Carcinoma)
Squamous Cell Carcinoma

COSMIC-021: Cabozantinib + Atezolizumab
(Head and Neck Cancer)
Head and Neck Cancer

Phase 2

Cabozantinib + Pembrolizumab
(Recurrent, Metastatic Squamous Cell Carcinoma)
Squamous Cell Carcinoma

Melanoma

Phase 2

Cabozantinib + Pembrolizumab
(Advanced, Metastatic Melanoma)
Melanoma

Cabozantinib + Nivolumab + Ipilimumab
(Unresectable, Advanced Melanoma)
Melanoma

Multiple Solid Tumor Types

Phase 1

Cabozantinib + Pemetrexed
(Advanced Non-Squamous NSCLC, UC, and Advanced Malignant Mesothelioma)
Non-Small Cell Lung Cancer / Urothelial Carcinoma / Mesothelioma

Pediatric Cancer

Phase 1

Cabozantinib + Retinoic Acid
Pediatric Multiple Tumor Types

Cabozantinib + pamiparib
(Advanced Solid Tumors)
Pediatric Cancer

Cabozantinib + nivolumab
(Multiple solid tumor types and HIV)
HIV / Multiple Solid Tumor Types

Phase 2

CaboMain: Cabozantinib
(High-risk Pediatric Solid Tumors)
Pediatric Multiple Tumor Types

Cabozantinib in Plexiform Neurofibromas
Pediatric Neurofibroma

Cabozantinib
(High-Grade Pediatric Glioma)
Pediatric Glioma

CABONE: Cabozantinib
(Osteosarcomas and Ewing Sarcomas; Patients 12+)
Pediatric Sarcoma

Cabozantinib
(Refractory Sarcoma, Wilms Tumor, Other Rare Tumors)
Pediatric Multiple Tumor Types

Other Partnered Compounds

We are also advancing cancer treatment through collaborations.

LEARN MORE

© Exelixis, Inc. 2022 Ethics & Compliance | Privacy | Terms of Use